Philippines Health News API

{
    "totalArticles": 106444,
    "articles": [
        {
            "id": "55279b00fc809c3e956cb7ff232920ad",
            "title": "DOH says challenge remains in Mindanao measles jabbing",
            "description": "DESPITE the conduct of the Measles-Rubella Supplemental Immunization Activity (MR-SIA) Phase 1 in Mindanao last February, the Department of Health (DOH)...",
            "content": "DESPITE the conduct of the Measles-Rubella Supplemental Immunization Activity (MR-SIA) Phase 1 in Mindanao last February, the Department of Health (DOH) said vaccination coverage in the Southern Philippines remains a challenge.\nDOH Spokesman Albert D... [666 chars]",
            "url": "https://www.sunstar.com.ph/manila/doh-says-challenge-remains-in-mindanao-measles-jabbing",
            "image": "https://media.assettype.com/sunstar%2Fimport%2Fuploads%2Fimages%2F2019%2F02%2F19%2F125626.jpg?w=1200&ar=40%3A21&auto=format%2Ccompress&ogImage=true&mode=crop&enlarge=true&overlay=false&overlay_position=bottom&overlay_width=100",
            "publishedAt": "2026-04-09T09:44:11Z",
            "lang": "en",
            "source": {
                "id": "5102a925ef3ce7bac2c2f17827f4a4be",
                "name": "SunStar Publishing Inc.",
                "url": "https://www.sunstar.com.ph"
            }
        },
        {
            "id": "5d6a0eafa1f269e75ee4391c152c9d25",
            "title": "Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program",
            "description": "•    Ecuador aims to become one of the first rabies free countries in Latin America.",
            "content": "• Ecuador aims to become one of the first rabies free countries in Latin America.\n• Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance.\n• Boehringer Ingelheim announces critical support t... [4815 chars]",
            "url": "https://www.manilatimes.net/2026/04/09/tmt-newswire/globenewswire/ecuador-free-of-rabies-project-accelerates-progress-toward-eliminating-dog-mediated-rabies-supported-by-boehringer-ingelheims-stop-rabies-program/2317010",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/04/09/1006528.png",
            "publishedAt": "2026-04-09T08:03:15Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "c77ef41408d87676421f5dac3f68cfe0",
            "title": "Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model",
            "description": "A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain cancer model that closely mimics human glioblastomaProvides compelling proof-of-concept for Trogenix's dual-payload gene therapy platform that combines direct tumour killing with immune activation to create durable protection against aggressive brain cancersPublished pre-clinical data underpins the Company’s transition to a clinical-stage oncology company, with patient dosing in its first clinical trial for glioblastoma expected in Q2 2026Edinburgh, UK, 08 April 2026 - Trogenix Ltd ('Trogenix”), a pioneering biotech company dedicated to developing innovative cancer therapies today announces the publication of its breakthrough pre-clinical data in Nature reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM). The research supports an innovative approach to potentially achieving curative responses with long-term immunological protection against GBM, the most lethal form of brain cancer. It underpins the Company’s transition to a clinical-stage oncology company, with patient dosing in its first clinical trial for glioblastoma expected in Q2 2026.",
            "content": "A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain cancer model that closely mimics human glioblastoma\nPro... [7254 chars]",
            "url": "https://www.manilatimes.net/2026/04/09/tmt-newswire/globenewswire/trogenix-announces-publication-of-breakthrough-pre-clinical-data-in-nature-demonstrating-complete-tumour-eradication-and-durable-protection-in-aggressive-brain-cancer-model/2316963",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/04/09/1006397.jpg",
            "publishedAt": "2026-04-09T06:02:00Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        }
    ]
}